Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has issued an update.
Satsuma Pharmaceuticals, a subsidiary of SNBL, has received U.S. FDA approval for Atzumi™, a nasal powder for the acute treatment of migraines. This approval marks a significant milestone for SNBL, showcasing their innovative intranasal drug delivery platform and potentially enhancing the quality of life for migraine sufferers.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japanese nonclinical contract research organization founded in 1957, offering a range of services for drug discovery and development. Its subsidiary, Satsuma Pharmaceuticals, focuses on creating therapeutic products for unmet medical needs, particularly in drug-device combination products delivered via inhalation.
YTD Price Performance: -14.07%
Average Trading Volume: 349,813
Technical Sentiment Signal: Buy
Current Market Cap: Yen58.49B
See more insights into 2395 stock on TipRanks’ Stock Analysis page.